Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Google 2009 PageRank: #2 Among Top Health News and Media Publications
Google 2009 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2009 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2009 PageRank: #2 News and Media Site for the Pharmaceutical Industry
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
Medical News Article on Cancer Prevention
Research from Memorial Sloan Kettering Cancer Center, Department of Medicine in the area of cancer prevention published
2009 JUN 29 -- Research findings, 'A phase II study of flavopiridol (Alvocidib) in combination with docetaxel in refractory, metastaticpancreatic cancer,' are discussed in a new report. "Pancreatic adenocarcinoma (PC) harbors frequent alterations in p16, resulting in cell cycle dysregulation. A phase I study of docetaxel and flavopiridol, a pan-cyclin-dependent kinase inhibitor, demonstrated encouraging clinical activity in PC," scientists in the United States report.
"This phase II study was designed to further define the efficacy and toxicity of this regimen in patients with previously treated PC. Patients with gemcitabine-refractory, metastatic...
In order to view the entire article, please read your options to the right
